Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q3 2025 · 10-Q
Revenue$784.51M$784.51M+11.7% vs Q3 2024 Net Income$2.37M$2.37MN/M vs Q3 2024 EPS Diluted$0.01$0.01— vs Q3 2024 Gross Profit$273,974,000+1.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$118,450,000−16.5% Free Cash Flowderived$106,152,000−15.0% Margins · derivedGross margin34.9%−3.5 pt vs Q3 2024
Operating margin9.0%−3.7 pt vs Q3 2024
Net margin0.3%+0.3 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 6, 2025 · 37 d after period end